Bullous pemphigoid in a 3-month-old infant: case report and literature review of this dermatosis in childhood

Penfigoide bolhoso em lactente de 3 meses: relato de caso e revisão de literatura da dermatose na infância

Eugenio Galdino de Mendonça Reis-Filho1 Tainah de Almeida Silva2 Luiza Helena de Lima Aguirre3 Carmelia Matos Santiago Reis4

DOI: http://dx.doi.org/10.1590/abd1806-4841.20132378

Abstract: Bullous pemphigoid is an autoimmune subepidermal blistering dermatosis that is uncommon in childhood. We report a case of a female infant, 3 months old, which presented clinical and laboratory data for the confirmatory diagnosis of bullous pemphigoid. The authors used immunohistochemical staining for collagen type IV that allowed the differentiation of bullous pemphigoid from other subepidermal bullous diseases. Opportunely we review the clinical, immunological, therapeutic and prognostic features of this pathology in children.

Keywords: Child; Collagen type IV; Pemphigoid, bullous; Skin diseases, vesiculobullous

INTRODUCTION

Bullous pemphigoid (BP) is an acquired disease that belongs to the group of autoimmune subepidermic bullous disorders. It features circulating autoantibodies against distinctive skin’s basal membrane antigens and adjacent mucous membrane’s antigens.1-6 Its incidence increases with age, contrary to almost all of the autoimmune disorders.1 It is uncommon for the disease to begin during childhood and even more so during infancy.2,7-11

BP has a polymorphic clinical presentation. Vesicles and blisters arise on erythematous or apparently healthy skin combined with pruriginous, erythematous infiltrated papules and plaques with irregular borders, annular and polycyclic configurations (sometimes similar to erythema multiforme), which may precede or coexist with blisters.1,2,4,6,11,12 Blisters are tight, with variable size, usually symmetrical and ungrouped, with serous and / or hemorrhagic contents.2 They are located primarily on flexural areas of the limbs, trunk and abdomen. Face, head and neck are often affected.1,2,6,8,11,12,13 Itching is characteristic. Nikolsky sign is negative.1 Diagnosis is based on clinical, histopathological and immunofluorescence exams, particularly DIF (direct immunofluorescence) and salt-split skin technique, traditionally used to differentiate BP from other immune subepidermal bullous diseases.1,2,4,6,11,12,13

The clinical, histopathological and immunopathologic characteristics of this disease during childhood overlap with those in the adult form.5,7,8
However, some peculiarities are present in childhood BP, such as preferential involvement of palmoplantar regions, oral and genital mucosae and face. Bullous pemphigoid during childhood has a benign, self-limited evolution, with good response to treatment with corticosteroids, lower recurrence rates and better prognosis when compared to the adult form.

**CLINICAL CASE**

White infant female, three months and fifteen days old, developed multiple tight bullae five days ago, initially on palms and soles, with progressive involvement of trunk, limbs and head, accompanied by papules and plaques associated or not to blisters. Parents were not consanguineous, denied fever or use of medications, as well as other comorbidities. Personal and family history of atopy, other cutaneous diseases or autoimmune disorders was negative. The patient was born vaginally, at term, without complications. Exclusively breastfed. The patient received the recommended vaccines, with the last dose about 45 days previously.

Dermatological examination revealed the presence of multiple vesicles and widespread tight blisters with serous content and in different sizes, affecting areas of normal as well as erythematous skin. She presented serohemorrhagic crusts, papules and annular urticarial erythematous plaques, some topped by vesicles and blisters. Lesions were located predominantly in the hands, feet, scalp, limbs, trunk and back. There were no mucosal lesions. Nikolsky sign was negative (Figures 1 to 6).

Complete blood count showed mild anemia (hemoglobin: 10.8 g / dL), eosinophilia (2,300 eosinophils/mm³ or 26% of total leukocytes) and thrombocytosis (585,000 platelets). Histopathology showed spongiotic dermatitis with subepidermal bullae rich in neutrophils and eosinophils. DIF detected the presence of linear IgG and C3 deposits along the subepidermal basal membrane zone. Immunohistochemical staining for type IV collagen was positive at the base of the blister, demonstrating that cleaving occurred above the lamina densa. Salt-split skin technique and IIFs (indirect immunofluorescence) could not be performed. (Figures 7 to 10)

The set of clinical and laboratory data confirmed the diagnosis of infantile bullous pemphigoid. Treatment was started with prednisolone 1mg/kg. After five days, due to partial response, the dose of prednisolone was increased to 2mg/kg/day. Reassessment after fifteen days showed good control of the lesions, with only sparse escape blisters. Vaccinations were suspended on account of the immunosuppressive doses of corticosteroids. In order to permit corticosteroid weaning, dapsone was initiated at 0.5 mg / kg. Previous control exams had shown...
Bullous pemphigoid in a 3-month-old infant: case report and literature review of dermatoses in childhood

**Figure 4:** Detail of the lower limbs with erythematous urticariiform plaques topped by blister and vesicles

**Figure 5:** Detail of superior trunk and limbs

**Figure 6:** Detail of the trunk with early lesions, and head with serohemorrhagic crusts

**Figure 7:** HE 10x: Spongiotic dermatitis with presence of subepidermal blister rich in neutrophils and eosinophils

**Figure 8:** HE 40x: Detail of subepidermal blister rich in neutrophils and eosinophils

**Figure 9:** DIF: Positive reaction for IgG in subepidermal basal membrane zone

normal G6PD levels and no subsequent worsening of anemia occurred with medication. Corticosteroid therapy was reduced by 0.5 mg / kg every two weeks until its full suspension, while dapsone was maintained at 0.5 mg / kg / day. Patient remained without skin lesions for three months, and resumed the use of vaccines without live antigens according to the national vaccination calendar. At nine months old, she received acellular conjugated vaccines (DTPA), anti hepatitis B, polio and meningococcal diseases, with subsequent display of new bullous lesions. Dapsone was increased to a dose of 1mg/kg and prednisolone 1mg/kg was initiated for a week. With regression of the clinical symptoms dapsone was maintained for six months in which period no new lesions appeared, even with the use of vaccines, so, the medication was discontinued. The patient is followed-up in the outpatient dermatology service, and she has been lesion-free for six months without any signs of recurrence to date.

DISCUSSION AND CONCLUSION

The precise incidence of bullous pemphigoid in children and other bullous dermatoses in childhood are unknown. The first case of juvenile BP confirmed by immunofluorescence was published in 1970. Since then, there has been a notable increase in published cases; currently there are just under 100 cases reported in childhood, a dozen in infants.

In BP, there is concrete evidence that circulating antibodies have a key role in disease pathogenesis, reacting against epidermic basal membrane antigens, proteins BP180 antigen (antigen-2 BP) and BP230 antigen (antigen-1 BP) causing tissue injury. These proteins are components of adhesion junctional complexes, or hemidesmosomes, expressed in stratified epithelia.

Bullous pemphigoid can simulate various dermatoses and be clinically indistinguishable from other bullous diseases of childhood, such as dermatitis herpetiformis, acquired epidermolysis bullosa, bullous systemic lupus erythematosus or linear IgA bullous dermatosis. Besides medical history, physical examination and histopathological analysis, we use tests such as immunofluorescence, indirect immunofluorescence (with salt-split skin technique), immunoblotting and ELISA for diagnosis.

In this case, the question is whether the prior administration of vaccines did act as a trigger for the formation of autoantigens against the basal membrane. It is suggested that, in these cases, induced BP occurs through modulation of immunity. The vaccine could unmask a subclinical BP inducing a nonspecific immune reactivation in genetically predisposed individuals. However, the true role of vaccine antigens in the emergence of the BP is still questioned.

The interruption of vaccination in children who have post-vaccination BP is not recommended. In the patient described here, vaccinations were discontinued during the period of immunosuppressive dose of prednisolone and resumed when the dose was 0.5 mg / kg / day.

Palpomplantar lesions are typical of childhood BP, especially in children under one year, and these were the initial lesions in the case reported. The widespread involvement predominates in infants. There were no mucosal lesions in our case, those being most commonly found in children older than 1 year.

Such differences in BP clinical features among infants and older children do not have defined pathogenesis, but may be explained by differences in the expression of BP antigens according to age. There is no difference in the prognosis or treatment.

The clinical, histopathological, DIF and IIF aspects of bullous pemphigoid can also be observed in epidermolysis bullosa acquisita (EBA), another subepidermal bullous disease. To differentiate them, we can use immunofluorescence with salt-split skin technique. In EBA and bullous systemic lupus erythematosus, IgG deposits are only found on the dermal side of the cleft (base of the blister), while in bullous pemphigoid deposits occur in the epidermal side (top of the blister) or, more rarely, on both sides, since the main BP antigens are in the upper portion of the lamina lucida.

In the case described here, we performed a low-cost method that determined the location of target autoantigens. The authors used a simple staining immunohistochemistry exam for type IV collagen in skin biopsies embedded in paraffin, allowing the differentiation of bullous pemphigoid from other subepidermal bullous diseases. The advantage of this method is that it is not necessary to perform new immunofluorescence reactions, with another sets of costs and techniques. Type IV collagen is a component of the lamina densa that in bullous pemphigoid will be detected in the base of the blister, since autoantibodies against antigens BP180 antigen (antigen-2

FIGURE 10: Cryostat section with immunohistochemical reaction for type IV collagen showing positivity on the base of the blister

PB) and BP230 antigen (antigen-1 PB) are located on hemidesmosomes plates, above the lamina densa. EBA, characterized by autoantibodies against type VII collagen present in the sublamina densa region, will have type IV collagen highlighted after staining, on the top part of the blister. Therefore, immunohistochemical staining for collagen type IV also aids in the diagnosis of subepidermal bullous diseases.4,22,23

BP therapy aims only to alleviate symptoms and shorten the duration of illness.7,9 Classically, the treatment of choice is performed with systemic corticosteroids at a dose of 1 to 2 mg/kg/day of prednisone, only enough to control the disease, and not to completely suppress the lesions.3,4,7,10,11,13,15,18 The systemic corticoid may be associated with dapsone, 1mg/kg/day, aiming at later reduction of the corticoid dose while continuing with sulfone, as described in the reported case.5,20

Contrary to what is observed in adults, the prognosis of BP in children is good because its clinical course is benign and self-limited, and lesions regress in one year or less, with rare cases lasting two years or more.6,8,11,13,15,18 As there is a possibility of spontaneous remission in childhood; treatment should not be aggressive or too toxic.9 The occurrence of relapses is infrequent.10

This disorder, although rare, should always be among the differential diagnosis of bullous dermatoses in infants and children, especially in cases of palm-plantar involvement, in which the lesions are tight, wide and with an erythematous base.7,9,11,12 The more precise knowledge of PB’s pathophysiology can incite the development of new immunomodulatory target specific treatments, with fewer side effects than the traditional treatments.1 The clinical aspects, diagnosis, treatment and management of cases can be challenging, so caution is advisable in these circumstances.1,11 This case confirmed most of the characteristics reviewed in the literature and had an excellent response to conventional therapy, achieving remission within the usual time frame.11

REFERENCES


ERRATA

There is a mistake in the dapsone dosage on page 965, in the last phrase of first column, v.88, n.6 of article “Bullous pemphigoid in a 3-month-old infant: case report and literature review of dermatoses in childhood”. The phrase should read as follows: “The systemic corticoid may be associated with dapsone, 1mg/kg/day, aiming at later reduction of the corticoid dose while continuing with sulfone, as described in the reported case.”7

MAILING ADDRESS:
Eugenio Galdino de Mendonça Reis-Filho
Setor Médico Hospitalar Norte, Quadra 101 - Asa Norte 70710-100 - Brasília - DF
Brazil
E-mail: eugeniodermato@gmail.com

How to cite this article: Reis-Filho E, Silva TA, Aguirre LHL, Reis CMS. Bullous pemphigoid in a 3-month-old infant: case report and literature review of dermatoses in childhood. An Bras Dermatol. 2013;88(6):961-5.